{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:14:48Z","timestamp":1754162088548,"version":"3.41.2"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Individuals with no history of coronary artery disease can develop acute coronary syndrome (ACS), often in the absence of major risk factors including low-density lipoprotein cholesterol (LDL-C). We identified risk factors and biomarkers that can help identify those at discordantly high risk of ACS with normal LDL-C using a novel validated coronary artery disease predictive algorithm (CADPA) incorporating biomarkers of endothelial injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Five-year predicted ACS risk was calculated for 6392 persons using CADPA. Persons were classified as low (&lt;3.5%), intermediate (3.5\u2013&lt;7.5%) or high (\u22657.5%) CADPA risk and by LDL-C levels &lt;130 mg\/dL (low) and \u2265130 mg\/dL (high) and whether in the discordantly low LDL-C (but high CADPA risk) or high LDL-C (but low\/intermediate CADPA risk) group. Multiple logistic regression identified risk factors and biomarkers that predicted discordance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>31% were classified as low (&lt;3.5%), 27% at intermediate (3.5\u2013&lt;7.5%) and 42% were at high risk (\u22657.5%). 28% of subjects were identified in the low LDL discordant risk group (LDL-C&lt; 130 mg\/dL but 5-year CADPA predicted risk \u22657.5%) and 19% in the high LDL discordant risk group (LDL-C \u2265 130 mg\/dL but 5-year CADPA risk of &lt;7.5%). Diabetes (odds ratio [OR], 2.84 [2.21\u20133.66]), male sex (OR, 2.83 [2.40\u20133.35]), family history (OR, 2.23 [1.88\u20132.64]) and active smoking (OR, 1.99 [1.50\u20132.62]) predicted low LDL risk discordance more than other risk factors (all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01). Increased serum soluble FAS, hemoglobin A1c and interleukin-16 were the biomarkers most independently associated with increased risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Discordance between LDL-C levels and ACS risk is common. Males with diabetes and a family history of myocardial infarction who are actively smoking may be at highest risk of developing ACS despite controlled LDL-C. Future studies should examine whether using the CADPA can help identify individuals that could benefit from earlier targeting of risk factor modification for the prevention of ACS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001076","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T15:00:11Z","timestamp":1623942011000},"page":"e51-e58","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Novel biomarker panel measuring endothelial injury identifies patients at risk of coronary artery syndrome and discordance with low-density lipoprotein cholesterol"],"prefix":"10.1097","volume":"33","author":[{"given":"Ned","family":"Premyodhin","sequence":"first","affiliation":[{"name":"Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Fan","sequence":"additional","affiliation":[{"name":"Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masood","family":"Younus","sequence":"additional","affiliation":[{"name":"Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Predictive Health Diagnostics, Irvine"},{"name":"GuardAHeart Foundation, Laguna Beach, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan D.","family":"Wong","sequence":"additional","affiliation":[{"name":"Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ahj.2008.08.010","article-title":"Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.","volume":"157","author":"Sachdeva","year":"2009","journal-title":"Am Heart J"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1161\/01.CIR.94.5.1175","article-title":"Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications.","volume":"94","author":"Wexler","year":"1996","journal-title":"Circulation"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacl.2016.06.011","article-title":"Prevalence of the American College of Cardiology\/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.","volume":"10","author":"Wong","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.atherosclerosis.2008.07.030","article-title":"Detection of occult coronary artery disease in asymptomatic individuals with diabetes mellitus using non-invasive cardiac angiography.","volume":"203","author":"Rivera","year":"2009","journal-title":"Atherosclerosis"},{"issue":"Suppl 1","key":"R5-20250729","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1089\/dia.2012.0011","article-title":"The glycocalyx and cardiovascular disease in diabetes: should we judge the endothelium by its cover?","volume":"14","author":"Lemkes","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/01.CIR.97.23.2307","article-title":"Apoptosis and related proteins in different stages of human atherosclerotic plaques.","volume":"97","author":"Kockx","year":"1998","journal-title":"Circulation"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1152\/physiolgenomics.00104.2007","article-title":"Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease.","volume":"31","author":"Ardigo","year":"2007","journal-title":"Physiol Genomics"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00380-006-0910-8","article-title":"Inflammatory markers in a 2-year follow-up of coronary artery disease.","volume":"21","author":"Mizia-Stec","year":"2006","journal-title":"Heart Vessels"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1185\/03007995.2012.742878","article-title":"Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts.","volume":"28","author":"Cross","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMe1507041","article-title":"Proof that lower is better\u2013LDL cholesterol and IMPROVE-IT.","volume":"372","author":"Jarcho","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients.","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.amjcard.2018.11.044","article-title":"Usefulness of a coronary artery disease predictive algorithm to predict global risk for cardiovascular disease and acute coronary syndrome.","volume":"123","author":"Younus","year":"2019","journal-title":"Am J Cardiol"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/17530059.2013.753055","article-title":"Analytical performance validation of a coronary heart disease risk assessment multi-analyte proteomic test.","volume":"7","author":"Nolan","year":"2013","journal-title":"Expert Opin Med Diagn"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0032-1306418","article-title":"The relationship of serum soluble fas ligand (sFasL) level with the extent of coronary artery disease.","volume":"21","author":"Sahinarslan","year":"2012","journal-title":"Int J Angiol"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4239\/wjd.v5.i5.678","article-title":"Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.","volume":"5","author":"Konya","year":"2014","journal-title":"World J Diabetes"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11886-015-0609-5","article-title":"Dyslipidemia and cardiovascular disease in women.","volume":"17","author":"C\u00edfkov\u00e1","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"R22-20250729","doi-asserted-by":"crossref","DOI":"10.1002\/smi.2928","article-title":"Psychological stress, cardiac symptoms, and cardiovascular risk in women with suspected ischemia but no obstructive coronary disease (INOCA).","author":"Gomez","year":"2020","journal-title":"Stress Health"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"R24-20250729","first-page":"e568","article-title":"CDC\/AHA workshop on markers of inflammation and cardiovascular disease.","volume":"110","author":"Wilson Peter","year":"2004","journal-title":"Circulation"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.","volume":"119","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7326\/0003-4819-156-6-201203200-00006","article-title":"Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.","volume":"156","author":"Kavousi","year":"2012","journal-title":"Ann Intern Med"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1152\/physiolgenomics.00001.2005","article-title":"Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease.","volume":"22","author":"Tabibiazar","year":"2005","journal-title":"Physiol Genomics"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1152\/physiolgenomics.00240.2005","article-title":"Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice.","volume":"25","author":"Tabibiazar","year":"2006","journal-title":"Physiol Genomics"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0733-8651(03)00080-8","article-title":"Report of the adult treatment panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults.","volume":"21","author":"Pasternak","year":"2003","journal-title":"Cardiol Clin"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3122\/jabfm.19.1.46","article-title":"Family physician\u2019s knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey.","volume":"19","author":"Eaton","year":"2006","journal-title":"J Am Board Fam Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:11:38Z","timestamp":1753812698000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001076","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}